Home Neoplasma 2023 Neoplasma Vol.70, No.3, p. 319–332, 2023

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.


Neoplasma Vol.70, No.3, p. 319–332, 2023

Title: Function, drug resistance and prognostic effect of AKR1C2 in human cancer
Author: Zhao Wang, Yue Feng, Jiayu Song, Di Sun, Yun-Yan Zhang

Abstract: Aldo-keto reductases (ARKs), a group of reductases that rely on nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) to catalyze carbonyl, are widely found in various organisms, which play an important role in the physiological and pathological processes of human. Aldo-keto reductase family 1 member C2 (AKR1C2) as a member of the human ARKs family, can regulate steroid hormones and is abnormally expressed in many cancers. According to whether the tumor can be affected by hormones, we divide malignancies into hormone-dependent and hormone-independent types. Studies have shown that AKR1C2 is involved in regulating tumor invasion, migration, and other malignant phenotypes, eliminating reactive oxygen species (ROS), promoting chemotherapy resistance of tumor cells, and has prognostic value in some cancers. Here, we focus on the role and clinical significance of AKR1C2 in different types of tumors.


Keywords: AKR1C2; cancer; steroid hormone metabolism; drug resistance
Published online: 24-Jul-2023
Year: 2023, Volume: 70, Issue: 3 Page From: 319, Page To: 332
doi:10.4149/neo_2023_230206N66


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.